エトフィブラート、エトフィブレート
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/11/21 16:32:13」(JST)
[Wiki en表示]
Etofibrate
|
Systematic (IUPAC) name |
2-[(pyridin-3-yl)carbonyloxy]ethyl 2-(4-chlorophenoxy)-2-methylpropanoate |
Clinical data |
AHFS/Drugs.com |
International Drug Names |
Pregnancy cat. |
? |
Legal status |
? |
Pharmacokinetic data |
Metabolism |
Hydrolyzed to clofibric acid and niacin |
Identifiers |
CAS number |
31637-97-5 |
ATC code |
C10AB09 |
PubChem |
CID 65777 |
ChemSpider |
59197 Y |
UNII |
23TF67G79M Y |
KEGG |
D07187 Y |
ChEMBL |
CHEMBL358150 Y |
Chemical data |
Formula |
C18H18ClNO5 |
Mol. mass |
363.792 g/mol |
SMILES
- O=C(OCCOC(=O)C(Oc1ccc(Cl)cc1)(C)C)c2cccnc2
|
InChI
-
InChI=1S/C18H18ClNO5/c1-18(2,25-15-7-5-14(19)6-8-15)17(22)24-11-10-23-16(21)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3 Y
Key:XXRVYAFBUDSLJX-UHFFFAOYSA-N Y
|
Y (what is this?) (verify)
|
Etofibrate is a fibrate. It is a combination of clofibrate and niacin, linked together by an ester bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to controlled-release formulations.[1]
References[edit]
- ^ Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA (2001). "Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects". Braz J Med Biol Res 34 (2): 177–82. doi:10.1590/S0100-879X2001000200004. PMID 11175492. Free full text
Lipid modifying agents (C10)
|
|
GI tract |
Cholesterol absorption inhibitors, NPC1L1
|
|
|
Bile acid sequestrants/resins (LDL)
|
- Cholestyramine
- Colestipol
- Colestilan
- Colextran
- Colesevelam
|
|
|
Liver |
Statins (HMG-CoA reductase, LDL)
|
- Simvastatin#
- Atorvastatin
- Fluvastatin
- Lovastatin
- Mevastatin
- Pitavastatin
- Pravastatin
- Rosuvastatin
- Cerivastatin‡
|
|
Niacin and derivatives (HDL and LDL)
|
- Niceritrol
- Niacin
- Nicofuranose
- Aluminium nicotinate
- Nicotinyl alcohol
- Acipimox
|
|
MTTP inhibitors (VLDL)
|
- Dirlotapide
- Lomitapide
- Mitratapide
|
|
|
Blood vessels |
Fibrates (PPAR)
|
- Clofibrate‡
- Bezafibrate
- Aluminium clofibrate
- Gemfibrozil
- Fenofibrate
- Simfibrate
- Ronifibrate
- Ciprofibrate
- Etofibrate
- Clofibride
- Clinofibrate
|
|
CETP inhibitors (HDL)
|
- Anacetrapib†
- Dalcetrapib§
- Evacetrapib§
- Torcetrapib†
|
|
|
Combinations |
- Niacin/lovastatin
- Niacin/simvastatin
- Ezetimibe/simvastatin
- Ezetimibe/atorvastatin
- Niacin/laropiprant
|
|
Other |
- Dextrothyroxine‡
- Probucol
- Tiadenol
- Benfluorex
- Meglutol
- Omega-3-triglycerides
- Magnesium pyridoxal 5-phosphate glutamate
- Policosanol
- Lapaquistat§
- Mipomersen
- Alipogene tiparvovec
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
mt, k, c/g/r/p/y/i, f/h/s/l/o/e, a/u, n, m
|
k, cgrp/y/i, f/h/s/l/o/e, au, n, m, epon
|
m (A16/C10), i (k, c/g/r/p/y/i, f/h/s/o/e, a/u, n, m)
|
|
|
|
English Journal
- Biodegradation of clofibric acid and identification of its metabolites.
- Salgado R1, Oehmen A, Carvalho G, Noronha JP, Reis MA.
- Journal of hazardous materials.J Hazard Mater.2012 Nov 30;241-242:182-9. doi: 10.1016/j.jhazmat.2012.09.029. Epub 2012 Sep 24.
- Clofibric acid (CLF) is the pharmaceutically active metabolite of lipid regulators clofibrate, etofibrate and etofyllinclofibrate, and it is considered both environmentally persistent and refractory. This work studied the biotransformation of CLF in aerobic sequencing batch reactors (SBRs) with mixe
- PMID 23062606
- Methods of chromatographic determination of medicines decreasing the level of cholesterol.
- Kublin E1, Kaczmarska-Graczyk B, Malanowicz E, Mazurek AP.
- Acta poloniae pharmaceutica.Acta Pol Pharm.2010 Sep-Oct;67(5):455-61.
- With reference to common application of HPLC to routine analytical tests on medicinal products decreasing the level of cholesterol, including three compounds from this group--fenofibrate, bezafibrate and etofibrate, we developed a new method for determining two other compounds--ciprofibrate and gemf
- PMID 20873411
- [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
- Emmerich KH1, Poritis N, Stelmane I, Klindzane M, Erbler H, Goldsteine J, Görtelmeyer R.
- Klinische Monatsblätter für Augenheilkunde.Klin Monbl Augenheilkd.2009 Jul;226(7):561-7. doi: 10.1055/s-0028-1109516. Epub 2009 Jul 30.
- INTRODUCTION: Diabetic retinopathy is the leading cause of vision loss or blindeness in working-age adults in the developed and developing countries. No curative treatments are available for diabetic retinopathy and the most common symptomatic treatment, laser photocoagulation, provides only partial
- PMID 19644802
Japanese Journal
- Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia
Related Links
- Etofibrate is a fibrate. It is a combination of clofibrate and niacin, linked together by an ester bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to controlled-release formulations.
- etofibrate: Hyperlipidaemias.. etofibrate. ... Mechanism of Action, For details of the mechanism of action, pharmacology and pharmacokinetics and toxicology ... click to view etofibrate · MIMS Class · Dyslipidaemic Agents. ATC Classification ...
Related Pictures
★リンクテーブル★
[★]
- 英
- etofibrate
- 関
- エトフィブレート
[★]
- 英
- etofibrate
- 関
- エトフィブラート